+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the safety and effectiveness of a minimally invasive device called the Alleviant ALV1 System in patients with chronic heart failure, specifically those with heart failure with preserved or mildly reduced ejection fraction HFpEFHFmrEF. This prospective, multicenter, randomized, double-blind trial compares the device procedure to a sham control in order to better understand its potential benefits and risks. Participants are randomly assigned to one of two groups. Those in the treatment group undergo cardiac imaging, femoral vein access, and receive the Alleviant ALV1 System device procedure, which creates an interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement without the device procedure. The study has a crossover design, allowing participants to experience both conditions during the trial. During the study, participants will have cardiac imaging and exercise right heart catheterization to monitor heart function and pressures. Researchers will evaluate a composite primary endpoint at 12 months to assess safety and efficacy. Participants will be monitored for ongoing health status while continuing stable guideline-directed medical therapy. The trial is expected to complete by December 2032.

Age: 40Years +All GendersPhase Not Applicable
93 locations
S

Actively Recruiting

This research aims to compare atrioventricular junction ablation AVJA with continued optimal medication treatment for patients who have cardiac resynchronization therapy CRT and permanent or recurrent persistent atrial fibrillation AF with suboptimal heart rate control despite optimal medication. The study will randomly assign participants to one of two groups to evaluate which approach better manages heart function and quality of life over time. Participants will be randomly divided into two groups in equal numbers. One group will undergo AVJA, a procedure that disrupts the electrical connection between the upper and lower chambers of the heart, performed soon after randomization and repeated if necessary. The other group will continue with optimal medication treatment prescribed by their physician. CRT devices will be programmed uniformly with a base rate of 70 bpm and rate response functions activated unless not tolerated. Throughout the study, all participants will be regularly monitored at outpatient clinics. Researchers will assess heart failure events, quality of life using standardized questionnaires, medication doses, and heart function classification over a 3-year period. Secondary outcomes include mortality rates, heart failure hospitalizations, blood biomarker changes, and hospitalization days. Participants may switch from medication to AVJA if clinical deterioration occurs. The total study duration extends to 3 years with comprehensive follow-up to track these outcomes.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
9 locations
E

Actively Recruiting

This research aims to collect safety and effectiveness data for the VDyne Transcatheter Tricuspid Valve Replacement System as a treatment for tricuspid regurgitation. The study supports obtaining the Conformit Europenne CE Mark for this device. It focuses on adults with severe tricuspid valve regurgitation and evaluates the devices impact on heart valve function and patient health. Participants will receive treatment using the VDyne System during the study. This investigational device is designed to replace the tricuspid valve via a catheter-based procedure. The study follows a single group receiving the VDyne System, with assessments occurring from baseline through up to one year after the procedure to monitor safety and treatment effects. Throughout the trial, participants will be monitored for major adverse events related to the device or procedure, changes in valve leakage, symptom status, functional ability measured by a six-minute walk test, and quality of life. Evaluations include imaging reviews and clinical assessments at 1 month, 3 months, 6 months, and 1 year post-procedure. The total study duration spans several years, with primary safety outcomes assessed within 30 days and longer-term follow-up extending to one year after treatment.

Age: 18Years +All GendersPhase Not Applicable
21 locations
C

Actively Recruiting

Researchers are evaluating the best timing for surgery in patients who have severe aortic regurgitation but do not yet show symptoms. This heart valve condition often affects younger men and can lead to serious heart changes if left untreated. The study compares early surgery guided by detailed heart imaging with the usual approach of monitoring patients and operating only when symptoms or advanced heart changes develop. The study involves two main groups one will receive early, state-of-the-art aortic valve surgery, including valve-sparing procedures or replacements, scheduled within three months after randomization. The other group will follow a watchful waiting strategy with regular check-ups and surgery only if clear indications arise during follow-up. All patients undergo advanced heart imaging, exercise tests, blood tests, and quality of life questionnaires at set intervals. Participants will have heart magnetic resonance imaging and echocardiography at the start and at 12 months, plus clinical exams and tests every six months. Researchers will monitor heart function, exercise capacity, blood markers, and quality of life. The main outcome is a composite safety and effectiveness measure 12 months after randomization. The study also tracks complications, hospitalizations, and survival over time, with careful follow-up planned through the study duration.

Age: 18Years +All GendersPhase Not Applicable
8 locations